SMAD4 and pancreatic adenocarcinoma: PDC expression of KRASG12V was confirmed by next-generation sequencing (NGS) (Supplemental Table 6) and Western blot analysis (Supplemental Figure 10A), and oncogene profiling with TP53, SMAD4, and CDKN2A mutations was consistent with PAAD characteristics.